BUPROPION HYDROCHLORIDE

First approved in 1985

Details

Stereochemistry	RACEMIC
Molecular Formula	C13H18ClNO.ClH
Molecular Weight	276.202
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

Cl.CC(NC(C)(C)C)C(=O)C1=CC(Cl)=CC=C1

InChI

InChIKey=HEYVINCGKDONRU-UHFFFAOYSA-N

InChI=1S/C13H18ClNO.ClH/c1-9(15-13(2,3)4)12(16)10-6-5-7-11(14)8-10;/h5-9,15H,1-4H3;1H

HIDE SMILES / InChI

Molecular Formula	C13H18ClNO
Molecular Weight	239.741
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/018644s039s040.pdf | http://www.emedexpert.com/facts/bupropion-facts.shtml
Curator's Comment: Description was created based on several sources, including https://www.drugbank.ca/drugs/DB01156 | http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm103318.htm

Bupropion, an antidepressant of the aminoketone class and a non-nicotine aid to smoking cessation, is chemically unrelated to tricyclic, tetracyclic, selective serotonin re-uptake inhibitor, or other known antidepressant agents. Compared to classical tricyclic antidepressants, Bupropion is a relatively weak inhibitor of the neuronal uptake of norepinephrine, serotonin, and dopamine. In addition, Bupropion does not inhibit monoamine oxidase. Bupropion produces dose-related central nervous system (CNS) stimulant effects in animals, as evidenced by increased locomotor activity, increased rates of responding in various schedule-controlled operant behavior tasks, and, at high doses, induction of mild stereotyped behavior. Bupropion is marketed as Wellbutrin, Zyban, and generics. Bupropion is indicated for the treatment of major depressive disorder (MDD). WELLBUTRIN, WELLBUTRIN SR, and WELLBUTRIN XL are not approved for smoking cessation treatment, but bupropion under the name ZYBAN is approved for this use.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Dopamine transporter 172 Target ID: CHEMBL238 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/018644s039s040.pdf \| https://www.ncbi.nlm.nih.gov/pubmed/19497387 \| https://www.ncbi.nlm.nih.gov/pubmed/9862757	Inhibitor 8146		550.0 nM [IC50]
Norepinephrine transporter 183 Target ID: CHEMBL222 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/018644s039s040.pdf \| https://www.ncbi.nlm.nih.gov/pubmed/19497387 \| https://www.ncbi.nlm.nih.gov/pubmed/9862757	Inhibitor 8146		443.0 nM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Major depressive disorder 172 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/018644s039s040.pdf	Primary		Approved 8307	WELLBUTRIN Approved Use INDICATIONS & USAGE Major Depressive Disorder:Bupropion hydrochloride extended-release tablets (XL) are indicated for the treatment of major depressive disorder. The efficacy of bupropion in the treatment of a major depressive episode was established in two 4-week controlled trials of inpatients and in one 6-week controlled trial of outpatients whose diagnoses corresponded most closely to the Major Depression category of the APA Diagnostic and Statistical Manual (DSM) (seeCLINICAL TRIALS). A major depressive episode (DSM-IV) implies the presence of 1) depressed mood or 2) loss of interest or pleasure; in addition, at least 5 of the following symptoms have been present during the same 2-week period and represent a change from previous functioning: depressed mood, markedly diminished interest or pleasure in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt, or suicidal ideation. The efficacy of bupropion in maintaining an antidepressant response for up to 44 weeks following 8 weeks of acute treatment was demonstrated in a placebo-controlled trial with the sustained-release formulation of bupropion (seeCLINICAL TRIALS). Nevertheless, the physician who elects to use bupropion hydrochloride extended-release tablets (XL) for extended periods should periodically reevaluate the long-term usefulness of the drug for the individual patient. Seasonal Affective Disorder:Bupropion hydrochloride extended-release tablets (XL) are indicated for the prevention of seasonal major depressive episodes in patients with a diagnosis of seasonal affective disorder. The efficacy of bupropion hydrochloride extended-release tablets (XL) for the prevention of seasonal major depressive episodes was established in 3 controlled trials of adult outpatients with a history of major depressive disorder with an autumn-winter seasonal pattern as defined by Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV) criteria (seeCLINICAL TRIALS). Seasonal affective disorder is characterized by recurrent major depressive episodes, most commonly occurring during the autumn and/or winter months. Episodes may last up to 6 months in duration, typically beginning in the autumn and remitting in the springtime. Although patients with seasonal affective disorder may have depressive episodes during other times of the year, the diagnosis of seasonal affective disorder requires that the number of seasonal episodes substantially outnumber the number of non-seasonal episodes during the individual's lifetime. Launch Date 5.04748802E11
Nicotine dependence 32 Sources: https://www.drugs.com/pro/zyban.html http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020711s034REMSZyban.pdf	Primary		Approved 8307	ZYBAN Approved Use Zyban is indicated as an aid to smoking cessation treatment. Launch Date 5.04748802E11

C_max

Value	Dose	Analyte	Population
134 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28685396	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	BUPROPION plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
93 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28685396	75 mg single, oral dose: 75 mg route of administration: Oral experiment type: SINGLE co-administered:	BUPROPION HYDROCHLORIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
136 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020711s026lbl.pdf	150 mg 2 times / day steady-state, oral dose: 150 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	BUPROPION HYDROCHLORIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
91 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020711s026lbl.pdf	150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered:	BUPROPION HYDROCHLORIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
688 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28685396	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:		BUPROPION plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
469 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28685396	75 mg single, oral dose: 75 mg route of administration: Oral experiment type: SINGLE co-administered:		BUPROPION HYDROCHLORIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

T_1/2

Value	Dose	Analyte	Population
10 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28685396	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	BUPROPION plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
10 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28685396	75 mg single, oral dose: 75 mg route of administration: Oral experiment type: SINGLE co-administered:	BUPROPION HYDROCHLORIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
21 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020711s026lbl.pdf	150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered:	BUPROPION HYDROCHLORIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
16% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020711s026lbl.pdf	150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered:		BUPROPION HYDROCHLORIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
900 mg 1 times / day multiple, oral Highest studied dose Dose: 900 mg, 1 times / day Route: oral Route: multiple Dose: 900 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/018644s043lbl.pdf	unhealthy, adult n = 214 Health Status: unhealthy Condition: depression Age Group: adult Sex: unknown Population Size: 214 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/018644s043lbl.pdf	Other AEs: Seizures... Other AEs: Seizures (2.8%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/018644s043lbl.pdf
600 mg 1 times / day multiple, oral (max) Recommended Dose: 600 mg, 1 times / day Route: oral Route: multiple Dose: 600 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/018644s043lbl.pdf	unhealthy, adult n = 2400 Health Status: unhealthy Condition: depression Age Group: adult Sex: unknown Population Size: 2400 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/018644s043lbl.pdf	Disc. AE: Neuropsychiatric symptoms, Gastrointestinal disturbance... Other AEs: Neuropsychiatric symptoms... AEs leading to discontinuation/dose reduction: Neuropsychiatric symptoms (3%) Gastrointestinal disturbance (2.1%) Neurological disorder NOS (1.7%) Skin and subcutaneous tissue disorders (1.4%) Other AEs: Neuropsychiatric symptoms Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/018644s043lbl.pdf

AEs

AE	Significance	Dose	Population
Seizures	2.8%	900 mg 1 times / day multiple, oral Highest studied dose Dose: 900 mg, 1 times / day Route: oral Route: multiple Dose: 900 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/018644s043lbl.pdf	unhealthy, adult n = 214 Health Status: unhealthy Condition: depression Age Group: adult Sex: unknown Population Size: 214 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/018644s043lbl.pdf
Neuropsychiatric symptoms		600 mg 1 times / day multiple, oral (max) Recommended Dose: 600 mg, 1 times / day Route: oral Route: multiple Dose: 600 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/018644s043lbl.pdf	unhealthy, adult n = 2400 Health Status: unhealthy Condition: depression Age Group: adult Sex: unknown Population Size: 2400 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/018644s043lbl.pdf
Skin and subcutaneous tissue disorders	1.4% Disc. AE	600 mg 1 times / day multiple, oral (max) Recommended Dose: 600 mg, 1 times / day Route: oral Route: multiple Dose: 600 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/018644s043lbl.pdf	unhealthy, adult n = 2400 Health Status: unhealthy Condition: depression Age Group: adult Sex: unknown Population Size: 2400 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/018644s043lbl.pdf
Neurological disorder NOS	1.7% Disc. AE	600 mg 1 times / day multiple, oral (max) Recommended Dose: 600 mg, 1 times / day Route: oral Route: multiple Dose: 600 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/018644s043lbl.pdf	unhealthy, adult n = 2400 Health Status: unhealthy Condition: depression Age Group: adult Sex: unknown Population Size: 2400 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/018644s043lbl.pdf
Gastrointestinal disturbance	2.1% Disc. AE	600 mg 1 times / day multiple, oral (max) Recommended Dose: 600 mg, 1 times / day Route: oral Route: multiple Dose: 600 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/018644s043lbl.pdf	unhealthy, adult n = 2400 Health Status: unhealthy Condition: depression Age Group: adult Sex: unknown Population Size: 2400 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/018644s043lbl.pdf
Neuropsychiatric symptoms	3% Disc. AE	600 mg 1 times / day multiple, oral (max) Recommended Dose: 600 mg, 1 times / day Route: oral Route: multiple Dose: 600 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/018644s043lbl.pdf	unhealthy, adult n = 2400 Health Status: unhealthy Condition: depression Age Group: adult Sex: unknown Population Size: 2400 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/018644s043lbl.pdf

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1670	substrate 985	inhibitor 1789	inhibitor 1570

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
P-gp 1401 OCT2 630	CYP2B6 648 P-gp 1491 CYP1A2 1013 CYP2A6 510 CYP2E1 633 CYP 252

Drug as perpetrator

Target	Modality	Activity	Clinical evidence
P-gp 1588	inhibitor 3185 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/021515_Wellbutrin_biopharmr.PDF Page: 30.0	inconclusive
OCT2 631	inhibitor 3185 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/200063Orig1s000ClinPharmR.pdf Page: 15.0	yes [IC50 9.3 uM]
CYP2D6 1826	inhibitor 3185 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/200063Orig1s000ClinPharmR.pdf Page: 90.0	yes	yes (co-administration study) Comment: from FDA label https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021515s040lbl.pdf: coadministration with desipramine increased the Cmax of desipramine by 2-fold, and AUC by 5-fold Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/200063Orig1s000ClinPharmR.pdf Page: 90.0

Drug as victim

Target	Modality	Activity	Clinical evidence
P-gp 1491	substrate 3264 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/021515_Wellbutrin_biopharmr.PDF Page: 30.0	inconclusive
CYP 252	substrate 3264 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022497Orig1s000ClinPharmR.pdf Page: 4, 43	likely
CYP1A2 1013	substrate 3264 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/20711_ZYBAN,%20100MG%20AND%20150MG_BIOPHARMR.PDF Page: 10.0	minor
CYP2A6 510	substrate 3264 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/20711_ZYBAN,%20100MG%20AND%20150MG_BIOPHARMR.PDF Page: 10.0	minor
CYP2C9 985	substrate 3264 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/20711_ZYBAN,%20100MG%20AND%20150MG_BIOPHARMR.PDF Page: 10.0	minor
CYP2E1 633	substrate 3264 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/20711_ZYBAN,%20100MG%20AND%20150MG_BIOPHARMR.PDF Page: 10.0	minor
CYP3A4 1670	substrate 3264 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/20711_ZYBAN,%20100MG%20AND%20150MG_BIOPHARMR.PDF Page: 10.0	minor
CYP2B6 648	substrate 3264 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/200063Orig1s000ClinPharmR.pdf Page: 10.0	yes	yes (co-administration study) Comment: from FDA label https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021515s040lbl.pdf: coadministration with ticlopidine increased buproprion Cmax 38% and AUC by 85% Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/200063Orig1s000ClinPharmR.pdf Page: 10.0

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 1603	inhibitor 1584 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/200063Orig1s000PharmR.pdf Page: 46.0

Sourcing

Vendor/Aggregator	ID	URL
ChemIDplus	93109989	https://chem.nlm.nih.gov/chemidplus/id/0093109989
PubChem	12882211	https://pubchem.ncbi.nlm.nih.gov/compound/12882211
SureChEMBL	SCHEMBL1235744	https://www.surechembl.org/chemical/SCHEMBL1235744

PubMed

Title	Date	PubMed
Sexual dysfunction associated with the treatment of depression: a placebo-controlled comparison of bupropion sustained release and sertraline treatment.	1999 Dec	10596735
Bupropion-induced isolated impairment of sensory trigeminal nerve function.	2000 Mar	10759343
Bupropion treatment-related sexual side effects: a case report.	2000 Mar	10742886
Visual and auditory hallucinations with the association of bupropion and valproate.	2000 Mar	10742884
Seizure after guanfacine plus bupropion: correction.	2000 Nov	11068884
Algorithm for the treatment of chronic depression.	2001	11310816
Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction.	2001	11229449
Modification of norepinephrine and serotonin, but not dopamine, neuron firing by sustained bupropion treatment.	2001 Apr	11374336
Bupropion overdose: a potential problem with the new 'miracle' anti-smoking drug.	2001 Apr	11351778
[Bupropion: a new hope for smokers willing to quit].	2001 Apr	11303406
Bupropion hydrochloride: the development of a chiral separation using an ovomucoid column.	2001 Apr 13	11355823
Techniques for smoking cessation: what really works?	2001 Feb	11233062
A free smoking intervention clinic initiated by medical students.	2001 Feb	11213302
Ritonavir, efavirenz, and nelfinavir inhibit CYP2B6 activity in vitro: potential drug interactions with bupropion.	2001 Feb	11159797
A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults.	2001 Feb	11156812
[Bupropion; an effective new aid for smoking cessation].	2001 Feb 10	11236376
[Risk of convulsions due to the use of bupropion as an aid for smoking cessation].	2001 Feb 10	11236375
Smoking cessation. Pulling out the stops.	2001 Feb 15	11246826
Bupropion for smokers. Where are practices supposed to find money for bupropion?	2001 Feb 17	11179167
Bupropion for smokers. Drug is almost identical in structure to diethylpropion, a controlled drug.	2001 Feb 17	11179153
Treatment of attention-deficit hyperactivity disorder.	2001 Jan	11237228
[Recent advances in research on nicotine dependence and reward mechanism].	2001 Jan	11233293
A 25-year-old woman with bipolar disorder.	2001 Jan 24-31	11242431
Treating nicotine dependence.	2001 Jan-Feb	11257836
Effects of cocaine prior to and during bupropion maintenance in cocaine-abusing volunteers.	2001 Jul 1	11376920
Bupropion manic induction during euthymia, but not during depression.	2001 Jun	11465677
The Stanley Foundation Bipolar Network. I. Rationale and methods.	2001 Jun	11450179
Bupropion-induced erythema multiforme.	2001 Jun	11393509
Variations in treatment benefits influence smoking cessation: results of a randomised controlled trial.	2001 Jun	11387540
Bupropion sustained-release for the treatment of dysthymic disorder: an open-label study.	2001 Jun	11386496
Tobacco-use cessation programs and policies at the University of Manitoba's faculty of dentistry.	2001 Mar	11315393
Substitution of an SSRI with bupropion sustained release following SSRI-induced sexual dysfunction.	2001 Mar	11305705
Smoking cessation. The key to treating older smokers? Don't quit helping.	2001 May	11373953
The use of bupropion in the treatment of restlessness after a traumatic brain injury.	2001 May	11350660
Use of bupropion SR in a pharmacist-managed outpatient smoking-cessation program.	2001 May	11349752
Bupropion for smoking cessation : predictors of successful outcome.	2001 May	11348939
Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial.	2001 May 19	11377644
Bupropion sustained release (SR) for the treatment of hypoactive sexual desire disorder (HSDD) in nondepressed women.	2001 May-Jun	11354935

Patents

Sample Use Guides

In Vivo Use Guide

The usual adult dose is 300 mg/day, given 3 times daily. Dosing should begin at 200 mg/day, given as 100 mg twice daily. Based on clinical response, this dose may be increased to 300 mg/day, given as 100 mg 3 times daily, no sooner than 3 days after beginning therapy.

Route of Administration: Oral

In Vitro Use Guide

Bupropion (10 uM) significantly decreased nicotine-evoked [(3)H]dopamine release by approximately 50% in rat striatal synaptosomes and slices.

Substance Class	Chemical Created by `admin` on `Fri Dec 16 20:50:49 UTC 2022` Edited by `admin` on `Fri Dec 16 20:50:49 UTC 2022`
Record UNII	ZG7E5POY8O
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

BUPROPION HYDROCHLORIDE

Official Name

English

BUPROPION HYDROCHLORIDE [JAN]

Common Name

English

BUPROPION HYDROCHLORIDE [ORANGE BOOK]

Common Name

English

BUPROPION HYDROCHLORIDE COMPONENT OF AUVELITY

Common Name

English

BUPROPION HYDROCHLORIDE [MI]

Common Name

English

BUPROPION HYDROCHLORIDE [USP-RS]

Common Name

English

NSC-315851

Code

English

BUPROPION HYDROCHLORIDE [USP IMPURITY]

Common Name

English

MYSIMBA

Brand Name

English

BUPROPION HYDROCHLORIDE COMPONENT OF CONTRAVE

Brand Name

English

BW-323

Code

English

BUPROPION HYDROCHLORIDE [USP MONOGRAPH]

Common Name

English

BUPROPION HYDROCHLORIDE [VANDF]

Common Name

English

1-PROPANONE, 1-(3-CHLOROPHENYL)-2-((1,1-DIMETHYLETHYL)AMINO)-, HYDROCHLORIDE, (±)-

Systematic Name

English

Bupropion hydrochloride [WHO-DD]

Common Name

English

BUPROPION HYDROCHLORIDE [USAN]

Common Name

English

BUPROPION HCL

Common Name

English

AUVELITY COMPONENT BUPROPION HYDROCHLORIDE

Common Name

English

BUPROPION HYDROCHLORIDE [MART.]

Common Name

English

AMFEBUTAMONE HYDROCHLORIDE

Common Name

English

BUPROPION HYDROCHLORIDE [HSDB]

Common Name

English

BW323

Code

English

CONTRAVE COMPONENT BUPROPION HYDROCHLORIDE

Brand Name

English

(±)-2-(TERT-BUTYLAMINO)-3'-CHLOROPROPIOPHENONE HYDROCHLORIDE

Systematic Name

English

WELLBUTRIN

Brand Name

English

Classification Tree Code System Code

EMA ASSESSMENT REPORTS

MYSIMBA (AUTHORIZED: OVERWEIGHT)

Created by admin on Fri Dec 16 20:50:49 UTC 2022 , Edited by admin on Fri Dec 16 20:50:49 UTC 2022

EMA ASSESSMENT REPORTS

MYSIMBA (AUTHORIZED: OBESITY)

Created by admin on Fri Dec 16 20:50:49 UTC 2022 , Edited by admin on Fri Dec 16 20:50:49 UTC 2022

NCI_THESAURUS

C265

Created by admin on Fri Dec 16 20:50:50 UTC 2022 , Edited by admin on Fri Dec 16 20:50:50 UTC 2022

Code System Code Type Description

MERCK INDEX

M2773

Created by admin on Fri Dec 16 20:50:49 UTC 2022 , Edited by admin on Fri Dec 16 20:50:49 UTC 2022

PRIMARY

Merck Index

PUBCHEM

62884

Created by admin on Fri Dec 16 20:50:50 UTC 2022 , Edited by admin on Fri Dec 16 20:50:50 UTC 2022

PRIMARY

FDA UNII

ZG7E5POY8O

Created by admin on Fri Dec 16 20:50:49 UTC 2022 , Edited by admin on Fri Dec 16 20:50:49 UTC 2022

PRIMARY

DRUG BANK

DBSALT000199

Created by admin on Fri Dec 16 20:50:49 UTC 2022 , Edited by admin on Fri Dec 16 20:50:49 UTC 2022

PRIMARY

NSC

315851

Created by admin on Fri Dec 16 20:50:50 UTC 2022 , Edited by admin on Fri Dec 16 20:50:50 UTC 2022

PRIMARY

CAS

31677-93-7

Created by admin on Fri Dec 16 20:50:49 UTC 2022 , Edited by admin on Fri Dec 16 20:50:49 UTC 2022

PRIMARY

DAILYMED

ZG7E5POY8O

Created by admin on Fri Dec 16 20:50:49 UTC 2022 , Edited by admin on Fri Dec 16 20:50:49 UTC 2022

PRIMARY

RS_ITEM_NUM

1078733

Created by admin on Fri Dec 16 20:50:50 UTC 2022 , Edited by admin on Fri Dec 16 20:50:50 UTC 2022

PRIMARY

EVMPD

SUB00432MIG

Created by admin on Fri Dec 16 20:50:49 UTC 2022 , Edited by admin on Fri Dec 16 20:50:49 UTC 2022

PRIMARY

RXCUI

203204

Created by admin on Fri Dec 16 20:50:50 UTC 2022 , Edited by admin on Fri Dec 16 20:50:50 UTC 2022

PRIMARY

RxNorm

EPA CompTox

DTXSID6044561

Created by admin on Fri Dec 16 20:50:49 UTC 2022 , Edited by admin on Fri Dec 16 20:50:49 UTC 2022

PRIMARY

ECHA (EC/EINECS)

250-759-9

Created by admin on Fri Dec 16 20:50:49 UTC 2022 , Edited by admin on Fri Dec 16 20:50:49 UTC 2022

PRIMARY

ChEMBL

CHEMBL894

Created by admin on Fri Dec 16 20:50:49 UTC 2022 , Edited by admin on Fri Dec 16 20:50:49 UTC 2022

PRIMARY

NCI_THESAURUS

C1317

Created by admin on Fri Dec 16 20:50:50 UTC 2022 , Edited by admin on Fri Dec 16 20:50:50 UTC 2022

PRIMARY

Related Record Type Details


					01ZG3TPX31

BUPROPION

PARENT -> SALT/SOLVATE

Amount:

Related Record Type Details


					5RQB4CW0AJ

1-PROPANONE, 2-((1,1-DIMETHYLETHYL)AMINO)-1-PHENYL-

IMPURITY -> PARENT

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

USP

Amount:


					YX53NS5D33

2-(TERT-BUTYLAMINO)-4'-CHLOROPROPIOPHENONE

IMPURITY -> PARENT

Amount:


					0RT1GZ9I8Z

1-(3,4-DICHLOROPHENYL)-2-((1,1-DIMETHYLETHYL)AMINO)-1-PROPANONE

IMPURITY -> PARENT

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

USP

Amount:


					BA7SW58FKS

2-(N-TERT-BUTYLAMINO)-3'-BROMOPROPIOPHENONE

IMPURITY -> PARENT

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

USP

Amount:


					0KQ3BNZ6CS

O-BUPROPION

IMPURITY -> PARENT

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

USP

Amount:


					3OP1CI6QQX

.ALPHA.-BROMO-3-CHLOROPROPIOPHENONE

IMPURITY -> PARENT

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

USP

Amount:


					XTY7LCB7MW

3-THIOMORPHOLINECARBOXYLIC ACID, 6-(3-CHLOROPHENYL)-6-HYDROXY-5-METHYL-, (3S,5R,6R)-

IMPURITY -> PARENT

Amount:


					UM2723PG76

1-(3-CHLOROPHENYL)PROPANE-1,2-DIONE

IMPURITY -> PARENT

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

USP

Amount:


					MZ54X0ANF3

5-CHLOROBUPROPION

IMPURITY -> PARENT

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

USP

Amount:


					494RAT7WFT

2-(TERT-BUTYLAMINO)-4'-CHLOROPROPIOPHENONE HYDROCHLORIDE

IMPURITY -> PARENT

Amount:


					02UOJ7064K

M-CHLOROBENZOIC ACID

IMPURITY -> PARENT

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

USP

Amount:


					2697RI8Z48

3'-CHLOROPROPIOPHENONE

IMPURITY -> PARENT

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

USP

Amount:

Related Record Type Details


					01ZG3TPX31

BUPROPION

ACTIVE MOIETY

Amount:

Details

SMILES

InChI

CNS Activity

Originator

Approval Year

Targets

Conditions

Approved Use

Launch Date

Approved Use

Launch Date

Cmax

AUC

T1/2

Funbound

Doses

AEs

Overview

OverviewOther

Drug as perpetrator​

Drug as victim

Tox targets

Sourcing

PubMed

Patents

Sample Use Guides

C_max

T_1/2

F_unbound

Drug as perpetrator